Ribostamycin is an aminoglycoside-aminocyclitol antibiotic derived from Streptomyces ribosidificus, utilized clinically to treat infections caused by susceptible Gram-negative bacteria, such as Pseudomonas… Read more
Ribostamycin is an aminoglycoside-aminocyclitol antibiotic derived from Streptomyces ribosidificus, utilized clinically to treat infections caused by susceptible Gram-negative bacteria, such as Pseudomonas aeruginosa. Its mechanism of action involves binding to the 30S ribosomal subunit to effectively inhibit bacterial protein synthesis. This category provides access to high-quality reference standards for Ribostamycin API, alongside a selection of its pharmacopeial and non-pharmacopeial impurities, such as Ribostamycin Impurity 1, and stable isotope-labelled compounds. These materials are essential for analytical testing, impurity profiling, and method validation within pharmaceutical laboratories. By utilizing these characterized reference standards, researchers and quality control scientists can accurately identify and quantify impurities during the drug manufacturing process, ensuring compliance with regulatory standards and maintaining the efficacy and safety of the final pharmaceutical product.